Field report E-65 / J5 · sheet /macro

Boardroom MacroFiled from the territory

North Dakota Caps Insulin at $25 a Month — in a Red State

North Dakota capped insulin at $25 a month with bipartisan votes, joining 28 other states. But state caps cannot reach federally regulated employer plans, and Congress is now weighing a $35 national limit.

Grid
E-65 / J5
Surveyed
November 16, 2026
Reading
5 min read
Correspondent
Sophie Lindqvist
Fed up with the healthcare industry, this red state capped insulin prices for patients
Fig. E-65 / J5Fed up with the healthcare industry, this red state capped insulin prices for patients — distelAPPArath / pixabay

Field notes

  1. North Dakota capped patient insulin costs at $25 a month, joining 28 other states with similar caps.
  2. Average out-of-pocket insulin costs for privately insured patients fell from $470 (2018) to $220 (2025).
  3. About 7 in 10 U.S. adults, including 68% of Republicans, say prescription drug prices lack sufficient regulation (KFF survey).
  4. A bipartisan Senate bill with 28 co-sponsors proposes a national $35 monthly insulin cap.
  5. State caps do not apply to health plans of larger employers, which are federally regulated.

North Dakota, a state with 42 Republican senators and five Democrats, has capped insulin costs at $25 a month for patients — one of 29 states that have enacted such measures. The bill passed last year with what observers describe as overwhelming bipartisan support, and a parallel proposal for a national $35 cap is now before Congress.

The state's decision illustrates a broader shift: drug price regulation, long a Democratic cause, is drawing Republican votes in statehouses across the country. What the caps deliver in practice, and what they leave untouched, is a more complicated picture.

What does the cap actually change?

The cap limits what patients pay out of pocket each month for insulin, even when a high deductible (the amount a patient must pay before insurance coverage begins) would otherwise force them to pay thousands of dollars first. It does not apply to physician visits, hospitalizations or other prescriptions.

It also does not apply to everyone. States can regulate only some health plans; insurance provided by larger employers typically falls under federal oversight. That gap is the caveat attached to every promise in this story.

The market that "just wasn't functioning"

The economics behind the cap are stark. Roughly a fifth of the estimated 40 million Americans with diabetes depend on insulin, a drug in commercial use for a century. Steep price hikes pushed average out-of-pocket costs to $470 a year in 2018 for people with private health insurance, according to federal data. Many patients rationed the drug, with sometimes deadly consequences.

Prices have since moderated — average yearly out-of-pocket costs fell to $220 in 2025 — but that decline followed public backlash against manufacturers, not a structural change. For families, a statutory cap offers protection against the next price cycle.

North Dakota state Sen. Sean Cleary, a Republican who co-sponsored the legislation, framed the case in market terms. "Typically, Republicans are more on the free-market side of things, Democrats are more supportive of intervening," he said. "But in this case, I think there was broad-enough agreement that this market just wasn't functioning for folks."

He added: "Why are folks paying hundreds of dollars a month for a drug that's been commercially available for decades? I just kept coming back to the fact that this market seems so broken and these families are having to make impossible decisions about rationing medication or skipping treatment."

Who opposed it, and on what grounds

Health insurers and the state chamber of commerce argued the cap would raise premiums for everyone else. "We do not make health insurance more affordable by passing coverage mandates," Blue Cross Blue Shield of North Dakota lobbyist Megan Hruby told lawmakers.

Janelle Moos, a state lobbyist for AARP, the advocacy group for older Americans that backed the bill, said industry arguments tapped a deep-seated skepticism. "It wasn't the role of government," she recalled GOP lawmakers telling her. "In a state like ours, we hear that all the time."

The counterargument came from data: supporters showed that a similar cap for state employees with diabetes had little measurable impact on insurance premiums. That evidence, combined with mounting frustration with drugmakers and insurers, moved the votes.

State Rep. Carrie McLeod, a Republican and a diabetes educator, put the criticism bluntly. "The insurance companies started out to really help people with catastrophic needs, but things have gotten out of control," she said.

The political trajectory

The strategy began with Democrats. Colorado enacted the first insulin copay cap in 2019, limiting state-regulated plans to $100 for a 30-day supply. In 2022, President Joe Biden signed legislation capping insulin at $35 a month for Medicare enrollees; a Democratic push to extend the cap to private insurance failed on Republican opposition.

In North Dakota, the legislative effort was led by state Sen. Tim Mathern, one of the chamber's five Democrats. "One is very lonely being a Democrat," he said, "especially if you espouse the more progressive end of public policy."

Polling now suggests the partisan gap has narrowed. In a KFF survey earlier this year, about 7 in 10 U.S. adults — including 68% of Republicans and 77% of Democrats — said there is not enough government regulation to limit prescription drug prices. In Congress, a bipartisan bill for a national $35 insulin cap counts 28 co-sponsors, among them Sen. Kevin Cramer, a North Dakota Republican.

What does this change for patients?

For a family like the Kritzbergers, who farm sugar beets, soybeans and grains in the Red River Valley and pay at least $8,000 a year out of pocket for diabetes drugs, supplies and appointments despite insurance, the cap removes one line of risk — the insulin itself. It does not touch the pumps, glucose monitors or hospital care that dominate their annual costs.

Their daughter Nina, 17, was diagnosed with Type 1 diabetes at age 7 and manages the disease's daily arithmetic. "I have to make sure I have insulin, a spare pump, a spare Dexcom," she said. "What if I go low? I need Gatorade, glucose." A missed dose, she said, means "my body would start attacking itself and start shutting down. And then I would die."

Her mother, Ang Kritzberger, testified at the Capitol in Bismarck alongside other families — initially against a wall of industry lobbyists. She views the outcome as evidence of something beyond policy. "We're very connected in North Dakota," she said, recalling neighbors who helped a farmer with brain cancer harvest his sugar beets. "It's all about being connected and finding that common ground."

Whether that common ground holds at the federal level, where a national cap would cover the employer-sponsored plans state laws cannot reach, is the question Congress has yet to answer.

via fortune.com/feed/ (Source)

Share this article:

More from Sophie Lindqvist

Sophie Lindqvist

Show full bio

Correspondent covering money, funding and market shifts around corporate strategy and chief-executive leadership at CEO Frontier.

483 articles

Filed under

Adjacent sheets

« Previous articleNext article »

End of sheetE-65 / J5 · November 16, 2026